{"id":11051,"date":"2025-05-16T12:34:19","date_gmt":"2025-05-16T12:34:19","guid":{"rendered":"https:\/\/sescs.es\/?page_id=11051"},"modified":"2025-05-29T14:51:09","modified_gmt":"2025-05-29T14:51:09","slug":"ttfields-glioblastoma","status":"publish","type":"page","link":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/","title":{"rendered":"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma"},"content":{"rendered":"<p><strong>Full title:<\/strong> Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma<\/p>\n<div>\n<p><strong>Authors:<\/strong> Rivero-Santana A, Ramos-Garc\u00eda V, Garc\u00eda-P\u00e9rez L, Toledo-Ch\u00e1varri A, Abt-Sacks A, Herrera-Ramos E, Ramallo-Fari\u00f1a Y, Caza\u00f1a-P\u00e9rez V, Favaro F, Pinto-Robayna B, \u00c1lvarez-P\u00e9rez Y, Guirado-Fuentes C, Duarte-D\u00edaz A, Capafons-Sosa JI, Solivera-Vera J, Garc\u00eda-Cabezas S, Perestelo-P\u00e9rez L<\/p>\n<p><strong>Contact person:<\/strong> Amado Rivero Santana (amado.riverosantana@sescs.es)<\/p>\n<p><strong>SUMMARY<\/strong><\/p>\n<p><strong>Introduction<\/strong><\/p>\n<\/div>\n<p>Glioblastoma (GBM) is the most common and aggressive primary brain tumor, with an extremely poor prognosis (median survival of 14 months and a 5-year survival rate below 10% with standard treatment). It is considered a rare disease, with an annual incidence ranging from 3 to 4.5 cases per 100,000 people. In the latest WHO classification (2021), the term glioblastoma is restricted to cases without mutations in the gene encoding isocitrate dehydrogenase (IDH) or histone H3 genes (referred to as wild-type H3 phenotype), which also present at least one of the following characteristics: microvascular proliferation, necrosis, TERT promoter mutation (Telomerase Reverse Transcriptase), copy number variations in chromosomes 7 and 10, or EGFR (Epidermal Growth Factor Receptor) gene amplifications.<\/p>\n<p>Clinical symptoms vary depending on the tumor\u2019s location, increasing intracranial pressure and leading to neurological complications that significantly affect quality of life: nausea, vomiting, headache, insomnia, depression, seizures, and focal neurological deficits such as visual disturbances, hemiparesis, or aphasia.<\/p>\n<p>The standard treatment for newly diagnosed GBM (ndGBM), known as the Stupp protocol, includes maximal surgical resection of the tumor followed by combined radiotherapy and chemotherapy with temozolomide (TMZ), an alkylating agent that inhibits DNA replication and induces cell death. The treatment lasts approximately six weeks, followed by a maintenance phase with TMZ alone during the first five days of each 28-day cycle, for a total of six cycles. The addition of TMZ to radiotherapy modestly increases patients&#8217; median survival, extending it from 12.1 to 14.6 months. However, only around 26% of patients survive more than two years, and fewer than 5% reach five-year survival.<\/p>\n<p>Over the past decades, new therapeutic approaches have been investigated for glioblastoma, including immunotherapy, antiangiogenic drugs, and other targeted therapies, but none have shown significant improvements in survival.<\/p>\n<p>Tumor Treating Fields (TTFields) therapy involves the application of low-intensity (1\u20133 V\/cm\u00b2), intermediate-frequency (100\u2013300 kHz) alternating electric fields. GBM treatment with TTFields is delivered using the portable Optune Gio\u00ae device (Novocure Ltd., Jersey, UK), which consists of an electric field generator, a connector box, and cables with transducers that apply the electric field. These transducers are adhered to the shaved scalp and strategically placed on the skull according to the tumor location identified by MRI. For therapeutic effect, it must be used for most of the day (at least 70% of the time).<\/p>\n<p>The system includes four rechargeable portable batteries (each lasting 2\u20133 hours), a plug-in power supply, and a shoulder bag for transport. The transducers must be replaced twice per week.<\/p>\n<p>In the United States, the FDA (Food and Drug Administration) approved this technology in 2011 for recurrent GBM and in 2015 for ndGBM in combination with TMZ during the maintenance phase following chemoradiotherapy. In Europe, TTFields therapy received CE marking and has been commercially available since 2009 for both indications.<\/p>\n<div>\n<p class=\"\" data-start=\"78\" data-end=\"92\"><strong data-start=\"78\" data-end=\"92\">Objectives<\/strong><\/p>\n<ul>\n<li data-start=\"94\" data-end=\"639\">To assess the effectiveness and safety of TTFields in the treatment of adults with newly diagnosed glioblastoma (ndGBM).<\/li>\n<li data-start=\"94\" data-end=\"639\">To evaluate the cost-effectiveness of TTFields in the treatment of adults with ndGBM.<\/li>\n<li data-start=\"94\" data-end=\"639\">To identify the ethical, legal, organizational, social, and environmental considerations related to the technology.<\/li>\n<li data-start=\"94\" data-end=\"639\">To identify research needs and standard outcome measures from the perspective of patients, family members\/caregivers, healthcare professionals, and researchers regarding the use of TTFields in the treatment of ndGBM.<\/li>\n<\/ul>\n<p class=\"\" data-start=\"87\" data-end=\"97\"><strong data-start=\"87\" data-end=\"97\">Method<\/strong><\/p>\n<p class=\"\" data-start=\"99\" data-end=\"320\">A systematic review (SR) of the available literature was conducted on the effectiveness, safety, cost-effectiveness, and ethical, legal, organizational, social, and environmental (ELOSE) aspects related to the technology.<\/p>\n<p class=\"\" data-start=\"322\" data-end=\"965\">The databases Medline, Embase, CINAHL, CDRS\/CENTRAL, and WPRIM &#8211; BRISA\/RedETSA &#8211; IBECS were searched from January 2011 to June 2024. Randomized controlled trials (RCTs), non-randomized controlled trials (NRCTs), controlled observational studies (COS), uncontrolled observational studies (UOS), economic evaluations (EE), cross-sectional and qualitative studies (ELOSE aspects), as well as systematic reviews (for all domains) and narrative reviews (ELOSE aspects) were considered. Additional information was requested from the industry regarding potential EE conducted in Spain, ongoing studies, and the environmental impact of the technology.<\/p>\n<p class=\"\" data-start=\"967\" data-end=\"1402\">Methodological quality was assessed using the following tools: AMSTAR-2 (for SRs), RoB-2 tool (RCTs), ROBINS-I tool (NRCTs and COS), Joanna Briggs Institute checklist (UOS), Drummond et al. criteria (EE), OSTEBA Critical Reading Checklist 3.0 (descriptive studies), CASPe tool (qualitative studies), and SANRA (narrative reviews). Study selection, risk of bias assessment, and data extraction were performed independently by reviewers.<\/p>\n<p class=\"\" data-start=\"1404\" data-end=\"2111\">For the synthesis of effectiveness and safety data, meta-analyses were conducted for the variables progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) were calculated to compare survival over time, as well as risk differences (RDs) to contrast rates at different time points. Pooled results were estimated using the inverse variance method. Heterogeneity was assessed using Cochran\u2019s Q and Higgins\u2019 I\u00b2 statistics. A random-effects model (Sidik-Jonkman) was used, and compared with a fixed-effects model when the I\u00b2 value was below 30%. A sensitivity analysis was performed by removing one study at a time. The synthesis of the SR on EE and ELOSE aspects was conducted narratively.<\/p>\n<p class=\"\" data-start=\"88\" data-end=\"99\"><strong data-start=\"88\" data-end=\"99\">Results<\/strong><\/p>\n<p class=\"\" data-start=\"101\" data-end=\"125\"><strong data-start=\"101\" data-end=\"125\">Effectiveness\/Safety<\/strong><\/p>\n<p class=\"\" data-start=\"127\" data-end=\"217\">A total of 16 studies were included: 1 SR, 1 RCT reported in 3 articles, 6 COS, and 6 UOS.<\/p>\n<p class=\"\" data-start=\"219\" data-end=\"254\"><em>Progression-Free Survival (PFS)<\/em><\/p>\n<p class=\"\" data-start=\"256\" data-end=\"814\">The EF-14 RCT reported median PFS (from randomization) of 6.7 months (TTFields) vs. 4.0 months (control), a statistically significant effect (HR = 0.63, 95% CI: 0.52, 0.76). The difference in the rate of progression-free patients was significantly higher with TTFields at 6 months (56% vs. 37%, RD = 19%, 95% CI: 15, 23). The difference was also significant at 1 year (30% vs. 20%, RD = 10%, 95% CI: 3, 17) but not at 2 years (14% vs. 10%, RD = 4%, 95% CI: -1, 9) (non-prespecified analyses in EF-14, performed by the report authors) (<strong>high-quality evidence<\/strong>).<\/p>\n<p class=\"\" data-start=\"816\" data-end=\"1071\">The meta-analysis (MA) of 4 COS found a similar result for PFS throughout the follow-up period (HR = 0.60, 95% CI: 0.47, 0.76; I\u00b2 = 35%), and higher rates at 6 months (RD = 24%, 95% CI: 9, 38; I\u00b2 = 78.4%) and 2 years (RD = 16%, 95% CI: 7, 26; I\u00b2 = 22.1%).<\/p>\n<p class=\"\" data-start=\"1073\" data-end=\"1098\"><em>Overall Survival (OS)<\/em><\/p>\n<p class=\"\" data-start=\"1100\" data-end=\"1516\">The EF-14 RCT reported median OS (from randomization) of 20.9 months (TTFields) vs. 16.0 months (control), a statistically significant effect (HR = 0.63, 95% CI: 0.53, 0.76). The difference in survival rates was significantly higher with TTFields at 2 years (RD = 12%, 95% CI: 4, 18), 3 years (RD = 10%, 95% CI: 3, 17), 4 years (RD = 12%, 95% CI: 5, 19), and 5 years (RD = 8%, 95% CI: 2, 14) (<strong>high-quality evidence<\/strong>).<\/p>\n<p class=\"\" data-start=\"1518\" data-end=\"1761\">The MA of 6 COS found similar results for OS throughout the follow-up period (HR = 0.67, 95% CI: 0.51, 0.88; I\u00b2 = 37.1%), as well as at 2 years (RD = 12%, 95% CI: 1, 24; I\u00b2 = 51.9%) and 4 years (4 studies; RD = 10%, 95% CI: 1, 18; I\u00b2 = 42.8%).<\/p>\n<p class=\"\" data-start=\"1763\" data-end=\"2070\">For both PFS and OS, the EF-14 study showed a significant intervention effect across all evaluated subgroups, based on sex, age (under 65 vs. 65 or older), geographic region (USA vs. other), type of resection (biopsy, partial, total), Karnofsky performance score (90\u2013100 vs. \u226480), and MGMT gene methylation.<\/p>\n<p class=\"\" data-start=\"2072\" data-end=\"2208\">Longer use time was associated with better OS outcomes in the EF-14 RCT and in the 5 observational studies that performed this analysis.<\/p>\n<p class=\"\" data-start=\"2210\" data-end=\"2244\"><em>Health-Related Quality of Life<\/em><\/p>\n<p class=\"\" data-start=\"2246\" data-end=\"2841\">The EF-14 RCT did not observe significant differences across 8 subscales assessed quarterly over one year: general health, physical health, cognitive, role, social, and emotional functioning, leg weakness, and pain. Significant differences were only observed in itching at the application site, with worse outcomes (higher scores) in the TTFields group (p &lt; 0.001 for the mixed-effects repeated measures model) at 3 months (10.4 vs. -2.3, p = 0.005), 6 months (8.1 vs. -4.2, p = 0.008), and 9 months (5.3 vs. -5.2, p = 0.04), but not at 12 months (4.6 vs. -1.9, p = 0.66) (<strong>low-quality evidence<\/strong>).<\/p>\n<p class=\"\" data-start=\"2843\" data-end=\"2853\"><strong data-start=\"2843\" data-end=\"2853\">Safety<\/strong><\/p>\n<p class=\"\" data-start=\"2855\" data-end=\"3174\">In the EF-14 RCT, no significant differences were found in the rate of patients experiencing at least one adverse event (AE) (96% vs. 91%) or in serious AEs (grade 3\u20134): TTFields: 48% vs. Control: 44% (p = 0.58). Skin-related AEs were more frequent in the intervention group; 52% were mild\/moderate and 2% were serious.<\/p>\n<p class=\"\" data-start=\"3176\" data-end=\"3470\">In a registry-based observational study (n = 5,887 with GBM), 51% experienced at least one AE possibly related to the device, the most frequent being local skin reactions (38%), followed by electrical sensations (11%) and heat (11%), headache (7%), pain (5%), fatigue (4%), and discomfort (2%).<\/p>\n<p class=\"\" data-start=\"3472\" data-end=\"3530\">The overall quality of the evidence was rated as <strong>moderate.<\/strong><\/p>\n<\/div>\n<p data-start=\"3472\" data-end=\"3530\"><strong data-start=\"0\" data-end=\"22\">Cost-effectiveness<\/strong><\/p>\n<div>\n<p class=\"\" data-start=\"24\" data-end=\"441\">Six economic evaluations comparing TTFields + TMZ to TMZ alone were included. The methodological quality was considered moderate. Four studies estimated ICERs well above \u20ac100,000\/QALY. A fifth study, conducted in China, estimated an ICER of \u20ac35,900\/QALY. The only Spanish study, unpublished and provided by the manufacturer, estimated an ICER of \u20ac152,273\/QALY from the perspective of the National Health System (NHS).<\/p>\n<p class=\"\" data-start=\"443\" data-end=\"512\"><strong data-start=\"443\" data-end=\"512\">Ethical, legal, organizational, social, and environmental aspects<\/strong><\/p>\n<p class=\"\" data-start=\"514\" data-end=\"1219\">The implementation of Optune\u00ae as an adjunct to conventional treatments for glioblastoma is well accepted by patients who adopt the technology. The reviewed literature has limitations in terms of the number of studies and the contextual relevance of the results, as all studies were conducted outside Spain. Aspects such as the impact on patients\u2019 quality of life, logistical and organizational requirements, and the necessary intensive involvement of the manufacturing company for device installation and technical support should be considered when evaluating adoption. Regarding equity, there is currently unequal access within the NHS, as the technology is only available in some Autonomous Communities.<\/p>\n<p class=\"\" data-start=\"0\" data-end=\"15\"><strong data-start=\"0\" data-end=\"15\">Conclusions<\/strong><\/p>\n<ul>\n<li data-start=\"17\" data-end=\"415\">There is high-quality evidence, represented by the EF-14 RCT, that TTFields (Optune\u00ae device), when applied concurrently with TMZ following chemoradiotherapy, significantly increases PFS and OS in adults with newly diagnosed glioblastoma (ndGBM). No evidence was found that this effectiveness varies significantly by sociodemographic or clinical characteristics, although further research is needed.<\/li>\n<li data-start=\"417\" data-end=\"726\">The average increase in survival is modest in absolute terms (2.7 months in PFS and 4.9 months in OS in EF-14), but relatively, it constitutes a clinically meaningful benefit given the poor survival outcomes with standard treatment. Moreover, the effect could potentially double with high device usage (\u226590%).<\/li>\n<li data-start=\"728\" data-end=\"943\">Observational evidence shows very similar survival outcomes (with a greater effect on PFS rates) and has demonstrated a significant and consistent relationship between daily device usage time and increased survival.<\/li>\n<li data-start=\"945\" data-end=\"1377\">Evidence on the impact of TTFields on health-related quality of life, also from the EF-14 study, has been rated as low quality. A significant deterioration was only observed due to pruritus at the application site. Regardless of disease progression\u2014which accounts for most quality-of-life decline\u2014there may be an increase in progression-free survival in some dimensions, such as pain or leg weakness, but further research is needed.<\/li>\n<li data-start=\"1379\" data-end=\"1847\">The device has shown a good safety profile (moderate quality evidence), with expected local skin-related adverse events (2% of them severe). In a registry study with over 5,800 patients with ndGBM, other possibly device-related adverse events included electric sensation, warmth, headache and scalp pain, fatigue, and discomfort, with incidence rates between 2\u201311%. These skin-related adverse events are expected to decrease with the latest version of the transducers.<\/li>\n<li data-start=\"1849\" data-end=\"1988\">Therefore, it can be stated with high confidence that, on average, TTFields offers a favorable risk-benefit balance in patients with ndGBM.<\/li>\n<li data-start=\"1990\" data-end=\"2255\">When comparing TTFields+TMZ with TMZ from the perspective of the Spanish NHS, the ICER in an industry-sponsored economic evaluation is estimated at approximately \u20ac150,000\/QALY. Most of the international economic evaluations identified also reported very high ICERs.<\/li>\n<\/ul>\n<p>DOCUMENTS:<\/p>\n<ol>\n<li><strong>Full report:<\/strong><\/li>\n<\/ol>\n<div>\n<p><span style=\"font-size: 12pt;\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-3880 alignleft\" src=\"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png\" alt=\"\" width=\"64\" height=\"64\" \/><\/span><\/p>\n<\/div>\n<div><\/div>\n<div class=\"wp-block-file\"><a href=\"https:\/\/sescs.es\/wp-content\/uploads\/2015\/09\/32_2024_SESCS_GLIOBLASTOMA_DEF_NIPO_290525.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-size: 12pt;\">SESCS Report &#8211; TTFields Glioblastoma &#8211; NIPO<\/span><span style=\"font-size: 12pt;\">.pdf<\/span><\/a><\/div>\n<\/div>\n<div><\/div>\n<div><\/div>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Full title: Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma Authors: Rivero-Santana A, Ramos-Garc\u00eda V, Garc\u00eda-P\u00e9rez L, &hellip; <\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[],"tags":[],"class_list":["post-11051","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS<\/title>\n<meta name=\"description\" content=\"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS\" \/>\n<meta property=\"og:description\" content=\"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/\" \/>\n<meta property=\"og:site_name\" content=\"SESCS\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SESCS2018\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T14:51:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png\" \/>\n\t<meta property=\"og:image:width\" content=\"64\" \/>\n\t<meta property=\"og:image:height\" content=\"64\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@_SESCS_\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/\",\"url\":\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/\",\"name\":\"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sescs.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sescs.es\\\/wp-content\\\/uploads\\\/2018\\\/06\\\/pdf.png\",\"datePublished\":\"2025-05-16T12:34:19+00:00\",\"dateModified\":\"2025-05-29T14:51:09+00:00\",\"description\":\"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/sescs.es\\\/en\\\/ttfields-glioblastoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sescs.es\\\/wp-content\\\/uploads\\\/2018\\\/06\\\/pdf.png\",\"contentUrl\":\"https:\\\/\\\/sescs.es\\\/wp-content\\\/uploads\\\/2018\\\/06\\\/pdf.png\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sescs.es\\\/#website\",\"url\":\"https:\\\/\\\/sescs.es\\\/\",\"name\":\"SESCS\",\"description\":\"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud - Reduciendo la incertidumbre en las decisiones\",\"publisher\":{\"@id\":\"https:\\\/\\\/sescs.es\\\/#organization\"},\"alternateName\":\"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sescs.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sescs.es\\\/#organization\",\"name\":\"SESCS\",\"alternateName\":\"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud\",\"url\":\"https:\\\/\\\/sescs.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/sescs.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sescs.es\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Imagen-noticia-Sescs-2.png\",\"contentUrl\":\"https:\\\/\\\/sescs.es\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Imagen-noticia-Sescs-2.png\",\"width\":956,\"height\":507,\"caption\":\"SESCS\"},\"image\":{\"@id\":\"https:\\\/\\\/sescs.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/SESCS2018\",\"https:\\\/\\\/x.com\\\/_SESCS_\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sescs-canarias\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS","description":"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/","og_locale":"en_US","og_type":"article","og_title":"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS","og_description":"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.","og_url":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/","og_site_name":"SESCS","article_publisher":"https:\/\/www.facebook.com\/SESCS2018","article_modified_time":"2025-05-29T14:51:09+00:00","og_image":[{"width":64,"height":64,"url":"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@_SESCS_","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/","url":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/","name":"Tumor Treating Fields (TTFields) therapy in people with newly diagnosed glioblastoma | SESCS","isPartOf":{"@id":"https:\/\/sescs.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/#primaryimage"},"image":{"@id":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/#primaryimage"},"thumbnailUrl":"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png","datePublished":"2025-05-16T12:34:19+00:00","dateModified":"2025-05-29T14:51:09+00:00","description":"El Servicio de Evaluaci\u00f3n y Planificaci\u00f3n del Servicio Canario de la Salud (SESCS) es una unidad dependiente de la Dir. del Servicio Canario de la Salud en la Cons. de Sanidad del Gobierno de Canarias, constituido por investigadores economistas, epidemi\u00f3logos, psic\u00f3logos, soci\u00f3logos, antrop\u00f3logos, bi\u00f3logos, estad\u00edsticos y evaluadores de servicios sanitarios.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sescs.es\/en\/ttfields-glioblastoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sescs.es\/en\/ttfields-glioblastoma\/#primaryimage","url":"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png","contentUrl":"https:\/\/sescs.es\/wp-content\/uploads\/2018\/06\/pdf.png"},{"@type":"WebSite","@id":"https:\/\/sescs.es\/#website","url":"https:\/\/sescs.es\/","name":"SESCS","description":"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud - Reduciendo la incertidumbre en las decisiones","publisher":{"@id":"https:\/\/sescs.es\/#organization"},"alternateName":"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sescs.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/sescs.es\/#organization","name":"SESCS","alternateName":"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud","url":"https:\/\/sescs.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/sescs.es\/#\/schema\/logo\/image\/","url":"https:\/\/sescs.es\/wp-content\/uploads\/2022\/04\/Imagen-noticia-Sescs-2.png","contentUrl":"https:\/\/sescs.es\/wp-content\/uploads\/2022\/04\/Imagen-noticia-Sescs-2.png","width":956,"height":507,"caption":"SESCS"},"image":{"@id":"https:\/\/sescs.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SESCS2018","https:\/\/x.com\/_SESCS_","https:\/\/www.linkedin.com\/company\/sescs-canarias\/"]}]}},"_links":{"self":[{"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/pages\/11051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/comments?post=11051"}],"version-history":[{"count":7,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/pages\/11051\/revisions"}],"predecessor-version":[{"id":11095,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/pages\/11051\/revisions\/11095"}],"wp:attachment":[{"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/media?parent=11051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/categories?post=11051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sescs.es\/en\/wp-json\/wp\/v2\/tags?post=11051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}